Athenex forges new deals in China and wins $100 million investment

3 July 2018

East Coast, USA-based firm Athenex (Nasdaq:ATNX), has announced several key strategic deals focused on China, aimed at furthering its oncology developments.

First, the firm says it has agreed a new joint venture (JV) with a subsidiary of Guangzhou Xiangxue Pharmaceutical to develop and commercialize T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, based on a novel approach.

At the same time, Athenex has made a strategic expansion into biologics for oncology, gaining worldwide rights to a pegylated genetically modified human arginase from a subsidiary of Hong Kong-based Avalon Biomedical Management.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK